AK-105
Phase 1Completed 0 watching 0 views this week💤 Quiet
32
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Advanced Cancer
Conditions
Advanced Cancer
Trial Timeline
Jan 2, 2018 → Oct 28, 2023
NCT ID
NCT03352531About AK-105
AK-105 is a phase 1 stage product being developed by Akeso for Advanced Cancer. The current trial status is completed. This product is registered under clinical trial identifier NCT03352531. Target conditions include Advanced Cancer.
Hype Score Breakdown
Clinical
10
Activity
5
Company
9
Novelty
3
Community
2
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03352531 | Phase 1 | Completed |
Competing Products
20 competing products in Advanced Cancer